Trials / Recruiting
RecruitingNCT06392568
Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units
Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units: A Prospective Multicenter National Observational Study (NOSOREA-3)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Abderrahmane Mami Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus.
Detailed description
In 2022, a previous one-day point-prevalence multicenter study (NOSOREA2, NCT05547646) showed that most prevalent pathogens causing healthcare-associated infections were carbapenem resistant enterobacteriaceae. In 2017, (NOSOREA1, LA TUNISIE MEDICALE - 2018 ; Vol 96 (10/11)), most prevalent pathogens were non-fermenting pathogens. Faced with this major epidemiological change within Tunisian ICUs, we decided to launch a 3rd survey under the aegis of the 'Association tunisienne de réanimation'. We aimed to investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus. So we conducted a multicenter prospective collection that will take place over 2 months.
Conditions
- Cross Infection
- Carbapenem Resistant Bacterial Infection
- Vancomycin-Resistant Enterococcal Infection
- Critical Illness
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | epidemiological records | Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
- First posted
- 2024-04-30
- Last updated
- 2024-04-30
Locations
1 site across 1 country: Tunisia
Source: ClinicalTrials.gov record NCT06392568. Inclusion in this directory is not an endorsement.